BioSpace News Archive

INSYS Therapeutics, Inc. announced today that it has reached an agreement in principle with the Department of Justice (DOJ) to settle the DOJ’s civil and criminal investigation into inappropriate sales and commercial practices by some former company employees. This agreement in principle is subject to the negotiation of final settlement documents with the government.

Initiated WINGS, the first clinical trial to evaluate the safety and efficacy of QR-313 in patients that have recessive dystrophic epidermolysis bullosa (RDEB) due to mutations in exon 73 of the COL7A1 gene

Patient Enrollment Underway in Global Phase III HOPE-B Pivotal Study of AMT-061

TOT BIOPHARM’s high-end oncology drug technology platform garners great attention

Second Quarter 2018 GAAP Revenue of $150.4 million, up 26% year over year

TraceLink Inc. announced its Russia compliance solution, providing companies with the ability to meet requirements for serialization, traceability, and compliance reporting for all pharmaceutical manufacturers that supply medicines to the Russian market, in advance of the country’s December 2019 enforcement deadline.

Paragon Bioservices announces two key leadership promotions.

Realm Therapeutics plc announces that Alex Martin, CEO, will be presenting at the 2018 Wedbush PacGrow Healthcare Conference, on Tuesday, August 14, 2018 at 4:15 p.m. ET at the Parker New York.

Second-quarter 2018 revenues of $715 million compared to second-quarter 2017 revenues of $876 million

AcelRx Pharmaceuticals, Inc. announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,090,909 shares of AcelRx’s common stock.